



Research of Small-Molecule Therapeutics in Transplantation and Tolerance

Guest Editor:

Dr. Kenneth J. Dery

David Geffen School of Medicine
at UCLA, Los Angeles, CA, USA

Deadline for manuscript
submissions:

30 November 2024

Message from the Guest Editor

Organ transplantation is the best curative treatment for patients with end-stage organ disease. An unavoidable complication leading to early allograft dysfunction is mediated primarily by ischemia-reperfusion injury (IRI). Understanding the mechanistic factors leading to I/R injury remains a top priority. Determining the peak induction potential of the signaling networks that attenuate antioxidant, detoxification, and homeostatic functions may be the key to understanding why specific therapeutic strategies fail to advance through clinical trials.

Small-molecule therapeutics, comprised of RNA, protein, and/or drug-based molecules, have achieved impressive results regulating gene expression networks involved in pro- and anti-inflammatory responses to organ transplantation injury. They have been shown to significantly increase the capacity to prevent organ rejection by reducing oxidative stress and inflammation, modulating the immune response, and stimulating the production of protective enzymes that promote tissue repair. This Special Issue's aim is to illustrate how these small molecules hold the potential to improve the survival of patients undergoing solid organ transplantation.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)